Delivery Order HHSN261201500018I-HHSN26100003
Award Date 9/15/16
Potential Completion Date 2/14/20
Potential Value $548K
Federal Agency
Ultimate Awardee
NAICS Category
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Houston, TX 77030, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
1
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This federal contract award, valued at $1,272,481.00, was issued by the National Cancer Institute to The University of Texas M.D. Anderson Cancer Center, a child entity of the University of Texas System. The contract is part of the "PREVENT Preclinical Drug Development Program (PREVENT)" and is focused on "TARGETING THE A2B ADENOSINE RECEPTOR FOR IMMUNOPREVENTION OF PANCREATIC CANCER." It is a firm fixed-price delivery order contract with a completion date of March 14,...
- The Department of Health and Human Services, National Institutes of Health, National Cancer Institute awarded a firm-fixed-price delivery order contract to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The $849,016 contract, which runs from September 17, 2018 to December 16, 2022, supports the "Rank Ligand Inhibition - A Potential Chemoprevention Strategy for Women at High Genetic Risk of Breast Cancer" project under the Preclinical...
- This is a Delivery Order issued against the National Institutes of Health's PREVENT Cancer Program (PREVENT) Indefinite Delivery/Indefinite Quantity (IDIQ) contract. The award, valued at $4,445.48, was made to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for a "CONTRACT ORIENTATION AND KICKOFF MEETING" related to the PRECLINICAL PREVENT CANCER PROGRAM initiative. The award has an ultimate completion date of December 31, 2015 and does...
- The National Cancer Institute issued a delivery order to The University of Texas MD Anderson Cancer Center on September 24, 2015, with a ceiling value of $4.2 million under the Cancer Prevention Agent Development Program 2012-2017 IDIQ for core infrastructure support of early-phase clinical research. Place of performance is Houston, TX. The order is priced on a cost-no-fee basis with an ultimate completion date of September 23, 2019. This delivery order represents Option 2 core infrastructure...
- This is a federal contract award from the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to the University of Texas MD Anderson Cancer Center (MD Anderson). The contract, valued at $20,094,324.00, is for the provision of cancer information services. The contract is a definitive contract with a cost-no-fee pricing type and has an ultimate completion date of January 14, 2010. MD Anderson, a comprehensive cancer treatment and research center, has received...
- This is a three-year, $13,481,325.00 definitive contract awarded by the National Cancer Institute (NCI) to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract supports a Phase II chemoprevention clinical trial in patients with adenomatous polyposis coli, a genetic condition that increases cancer risk. The contract does not have a small business set-aside designation. MD Anderson Cancer Center, a comprehensive cancer research and...
- This is a firm fixed price delivery order awarded by the Department of Health and Human Services National Institutes of Health National Cancer Institute to the University of Texas MD Anderson Cancer Center, a component of the University of Texas System. The contract, valued at $728,679.40, is for research to support the "Prevention of Hepatocellular Carcinoma (HCC) Associated with Non-Alcoholic Steatohepatitis (NASH)". The contract is part of the National Cancer Institute's...
- The University of Texas M.D. Anderson Cancer Center has been awarded a $632,712 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ contract by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. The delivery order is for the task of conducting preclinical efficacy and intermediate biomarker studies to develop an induced pluripotent stem cell-based vaccine for the...
- This is a $1,253,018.75 delivery order awarded by the Department of Health and Human Services' National Institutes of Health National Cancer Institute to The University of Texas MD Anderson Cancer Center, a component of the University of Texas System, for the VADIS TRIAL: PHASE II TRIAL OF E75 PEPTIDE VACCINE IN WOMEN WITH DCIS OF THE BREAST. The contract is part of the larger Cancer Prevention Agent Development Program 2012-2017 indefinite delivery contract. The award supports an early phase...
- The National Cancer Institute awarded a $1.14M firm fixed-price delivery order to The University of Texas MD Anderson Cancer Center for research on time-restricted feeding as a potential pancreatic cancer prevention strategy. This delivery order is part of MD Anderson's larger $149.995B Preclinical Efficacy & Intermediate Endpoint Biomarkers Indefinite Delivery/Indefinite Quantity (IDIQ) contract with NCI, which remains active through January 2029 and supports comprehensive preclinical...